Abstract
Cell separation technologies play a vital role in the graft engineering of hematopoietic cellular fractions, particularly with the rapid expansion of the field of cellular therapeutics. The CliniMACS Plus Instrument (Miltenyi Biotec) utilizes immunomagnetic techniques to isolate hematopoietic progenitor cells (HPCs), T cells, NK cells, and monocytes. These products are ultimately used for HPC transplantation and for the manufacture of adoptive immunotherapies. We evaluated the viable cell recovery and cell purity of selections and depletions performed on the CliniMACS Plus over a 10-year period at our facility, specifically assessing for the isolation of CD34+, CD4+, CD3+/CD56+, CD4+/CD8+, and CD25+ cells. Additionally, patient- and instrument-related factors affecting these parameters were examined. Viable cell recovery ranged from 32.3 ± 10.2% to 65.4 ± 15.4%, and was the highest for CD34+ selections. Cell purity ranged from 86.3 ± 7.2% to 99.0 ± 1.1%, and was the highest for CD4+ selections. Undesired cell fractions demonstrated a range of 1.2 ± 0.45 to 5.1 ± 0.4 log reductions. Red cell depletions averaged 2.12 ± 0.68 logs, while platelets were reduced by an average of 4.01 ± 1.57 logs. Donor characteristics did not impact viable cell recovery or cell purity for CD34+ or CD4+ cell enrichments; however, these were affected by manufacturing variables, including tubing size, bead quantity, and whether preselection platelet washes were performed. Our data demonstrate the efficient recovery of hematopoietic cellular fractions on the CliniMACS Plus that may be optimized by adjusting manufacturing variables.
Article PDF
Avoid common mistakes on your manuscript.
References
Freireich, EJ. Supportive care for patients with blood disorders. Br J Haematol 2000;111;68–77.
Giangrande, PL. The history of blood transfusion. Br J Haematol 2000;110;758–67.
Jones, AL. The IBM blood cell separator and blood cell processor: a personal perspective. J Clin Apher 1988;4;171–82.
Tomlinson, MJ, et al. Cell separation: terminology and practical considerations. J Tissue Eng 2013;4;2041731412472690.
Avecilla, ST, et al. How do I perform hematopoietic progenitor cell selection? Transfusion 2016;56;1008–12.
Bleakley, M, et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest 2015;125;2677–89.
Cho, C, et al. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis. Bone Marrow Transplant 2017;52;1629–36.
Turtle, CJ, et al. CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. J Clin Invest 2016;126; 2123–38.
Mavers, M, Bertaina, A. High-risk leukemia: past, present, and future role of NK cells. J Immunol Res 2018;2018;1586905.
Nikiforow, S, et al. A phase I study of CD25/regulatory T-celldepleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica 2016;101;1251–9.
Polouckova, A, et al. Comparison of two different methods for CD34+ selection and T cell depletion in peripheral blood stem cell grafts—our experiences with CellPro, E rosetting and CliniMACS technique. Neoplasma 2001;48;374–81.
Blake, JM, et al. Improved immunomagnetic enrichment of CD34(+) cells from umbilical cord blood using the CliniMACS cell separation system. Cytotherapy 2012;14;818–22.
Gaipa, G, et al. Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases. Bone Marrow Transplant 2003;31;857–60.
Keever-Taylor, CA, et al. Characteristics of CliniMACS(R) system CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant 2012;18;690–7.
Ghobadi, A, et al. Fresh or cryopreserved CD34(+)-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2017;23;1072–7.
Campbell, JD, et al. Isolation and generation of clinical-grade dendritic cells using the CliniMACS system. Methods Mol Med 2005;109;55–70.
Fehniger, TA, et al. A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 2018;24;1581–9.
Zhang, W, et al. An innovative method to generate a good manufacturing practice-ready regulatory T-cell product from nonmobilized leukapheresis donors. Cytotherapy 2015;17;1268–79.
Schumm, M, et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J Hematother 1999;8;209–18.
Vasu, S, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008;112;2092–100.
Spohn, G, et al. Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotherapy 2015;17;1465–71.
Stroncek, DF, et al. Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates. Transfusion 2016;56;511–17.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Data availability statement: Data are available in the NIH Center for Cellular Engineering Repository but are not available on public databases.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (https://doi.org/creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Panch, S.R., Reddy, O.L., Li, K. et al. Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument. Clin Hematol Int 1, 161–167 (2019). https://doi.org/10.2991/chi.d.190529.001
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.190529.001